Christopher Lowe

Horizon Discovery Group Ltd. is a cell engineering company, which engages in the design and engineering of genetically-modified cells. The firm operates through the following business segments: Products, Services, and Leveraged Research & Development. The Products segment sells cell lines and other products. The Services segment offers cell line manufacturing services. The Leveraged Research & Development segment business unit is operated on a portfolio basis. It serves pharmaceutical, biotechnology, and diagnostic companies. The company was founded by Christopher John Torrance, Adam John Collier, and Alberto Bardelli in July 2005 and is headquartered in Cambridge, the United Kingdom.